COVID-19 in Patients With Chronic Liver Diseases
- Conditions
- Chronic Liver DiseaseCOVID-19
- Interventions
- Other: Prospective Chart Review
- Registration Number
- NCT04439084
- Lead Sponsor
- Stanford University
- Brief Summary
This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1025
-
Confirmed diagnosis of COVID-19
-
Personal history of either
- Chronic hepatitis C
- Chronic hepatitis B
- Alcoholic liver disease
- Non alcoholic liver disease
- Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis
- Cryptogenic cirrhosis
- Hepatocellular carcinoma
- Non-COVID-19 patient
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic Liver Disease Group Prospective Chart Review COVID-19 patients with Chronic Liver Disease. Control Group Prospective Chart Review COVID-19 patients without Chronic Liver Disease.
- Primary Outcome Measures
Name Time Method Liver-related mortality 1 year Death due to liver-related cause
All-cause mortality 1 year Death due to any cause
Overall survival Up to 1 year Patients will be assessed for this outcome for up to 1 year
Number of patients with hepatic decompensation Up to 1 year Onset of hepatic decompensation due to COVID-19 disease; patients will be assessed for this outcome for up to 1 year
- Secondary Outcome Measures
Name Time Method Number of participants requiring mechanical ventilation Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Duration of hospitalization Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Length of intensive care unit (ICU) stay Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Number of patients requiring hospitalization Up to 1 year Patients will be assessed for this outcome for up to 1 year.
Trial Locations
- Locations (23)
University of Pennsylvania
๐บ๐ธPhiladelphia, Pennsylvania, United States
University of Southern California
๐บ๐ธLos Angeles, California, United States
University of Pittsburgh Medical Center
๐บ๐ธPittsburgh, Pennsylvania, United States
Mayo Clinic
๐บ๐ธScottsdale, Arizona, United States
Georgetown University
๐บ๐ธWashington, District of Columbia, United States
VA Medical Center
๐บ๐ธWashington, District of Columbia, United States
Massachusetts General Hospital
๐บ๐ธBoston, Massachusetts, United States
Brigham and Women's Hospital
๐บ๐ธBoston, Massachusetts, United States
Beth Israel Deaconess Medical Center
๐บ๐ธBoston, Massachusetts, United States
University of Miami
๐บ๐ธMiami, Florida, United States
Oschner Medical Center
๐บ๐ธBaton Rouge, Louisiana, United States
Hennepin County Medical Center (HCMC)
๐บ๐ธMinneapolis, Minnesota, United States
Duke University
๐บ๐ธDurham, North Carolina, United States
University of Arizona,
๐บ๐ธPhoenix, Arizona, United States
UCSF Fresno
๐บ๐ธFresno, California, United States
Stanford University
๐บ๐ธStanford, California, United States
Rush University Medical Center
๐บ๐ธChicago, Illinois, United States
The University of Kansas Medical Center
๐บ๐ธKansas City, Kansas, United States
Mount Sinai School of Medicine
๐บ๐ธNew York, New York, United States
Weill Cornell Medicine
๐บ๐ธNew York, New York, United States
University Hospitals Cleveland Medical Center
๐บ๐ธCleveland, Ohio, United States
University of Michigan
๐บ๐ธAnn Arbor, Michigan, United States
University of Minnesota
๐บ๐ธMinneapolis, Minnesota, United States